Next Article in Journal
The Double-Edged Sword Role of Viruses in Gastric Cancer
Next Article in Special Issue
The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
Previous Article in Journal
Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis
Previous Article in Special Issue
Cysteine Cathepsins Inhibition Affects Their Expression and Human Renal Cancer Cell Phenotype
Article

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

1
ARTIC (Association pour la Recherche sur les Thérapeutiques Innovantes en Cancérologie), Hôpital Européen Georges Pompidou, 75015 Paris, France
2
Department of Medical Oncology, Centre Antoine-Lacassagne, 06100 Nice, France
3
Department of Medical Oncology, Hôpital civil, 67091 Strasbourg, France
4
Department of Medical Oncology, Hôpital St Andre, 33000 Bordeaux, France
5
Department of Medical Oncology, Hôpital Européen Georges Pompidou, 75015 Paris, France
*
Author to whom correspondence should be addressed.
These two authors contributed equally to this work.
Cancers 2020, 12(6), 1673; https://doi.org/10.3390/cancers12061673
Received: 19 May 2020 / Revised: 19 June 2020 / Accepted: 21 June 2020 / Published: 24 June 2020
(This article belongs to the Special Issue Advances in the Treatment of Renal Cell Carcinoma)
Three drug combinations, ipilimumab-nivolumab (Ipi-Nivo), pembrolizumab-axitinib (Pembro-Axi), and avelumab-axitinib (Ave-Axi), have received regulatory approval in the USA and Europe for the treatment of metastatic renal cell carcinoma with clear cell component (mRCC). However, no head-to-head comparison data are available to identify the best option. Therefore, we aimed to compare these new treatments in a first-line setting. We conducted a systematic search in PubMed, the Cochrane Library, and clinicaltrials.gov for any randomized controlled trials of treatment-naïve patients with mRCC, from January 2015 to October 2019. The process was performed according to PRISMA guidelines. We performed a Bayesian network meta-analysis with two different approaches, a contrast-based model comparing HRs and ORs between studies and arm-based using parametric modeling. The outcomes for the analysis were overall survival, progression-free survival (PFS), and objective response rate. Our search identified 3 published phase 3 randomized clinical trials (2835 patients). In the contrast-based model, Ave-Axi (SUCRA = 83%) and Pembro-Axi (SUCRA = 80%) exhibited the best ranking probabilities for PFS. For overall survival (OS), Pembro-Axi (SUCRA = 96%) was the most preferable option against Ave-Axi and Ipi-Nivo. Objective response rate analysis showed Ave-Axi as the best (SUCRA: 94%) and Pembro-Axi as the second best option. In the parametric models, the risk of progression was comparable for Ave-Axi and Ipi-Nivo, whereas Pembro-Axi exhibited a lower risk during the first 6 months of treatment and a higher risk afterwards. Furthermore, Pembro-Axi exhibited a net advantage in terms of OS over the two other regimens, while Ave-Axi was the least preferable option. Overall evidence suggests that pembrolizumab plus axitinib seems to have a slight advantage over the other two combinations. View Full-Text
Keywords: metastatic renal cell carcinoma; immune-based combination therapies; network meta-analysis metastatic renal cell carcinoma; immune-based combination therapies; network meta-analysis
Show Figures

Figure 1

MDPI and ACS Style

Elaidi, R.; Phan, L.; Borchiellini, D.; Barthelemy, P.; Ravaud, A.; Oudard, S.; Vano, Y. Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Cancers 2020, 12, 1673. https://doi.org/10.3390/cancers12061673

AMA Style

Elaidi R, Phan L, Borchiellini D, Barthelemy P, Ravaud A, Oudard S, Vano Y. Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Cancers. 2020; 12(6):1673. https://doi.org/10.3390/cancers12061673

Chicago/Turabian Style

Elaidi, Reza, Letuan Phan, Delphine Borchiellini, Philippe Barthelemy, Alain Ravaud, Stéphane Oudard, and Yann Vano. 2020. "Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis" Cancers 12, no. 6: 1673. https://doi.org/10.3390/cancers12061673

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop